Sarcoma  >>  tivantinib (ARQ 197)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
NCT00557609 / 2009-011669-10: Phase 2 Study in Patients With MiT Tumors

Completed
2
47
US, Canada, Europe
ARQ 197
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
12/10
02/11
NCT01861301: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Terminated
2
18
US
Laboratory Biomarker Analysis, Tivantinib, ARQ 197, ARQ-197, c-Met Inhibitor ARQ 197
National Cancer Institute (NCI)
Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma, Stage III Pleural Mesothelioma, Stage IV Pleural Mesothelioma
03/15
03/15

Download Options